Bora Pharmaceuticals Co (TPE:6472) EPS without NRI: NT$33.25 (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:6472 Bora Pharmaceuticals Co Ltd TPE:6472
83 GF Score
Price NT$396.00
GF Value NT$736.58
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is Bora Pharmaceuticals Co EPS without NRI?

Bora Pharmaceuticals Co TPE:6472 -4.69% 83 EPS without NRI is NT$33.25 as of Dec. 2025. GuruFocus rates TPE:6472 with a GF Score™ of 83/100 and a GF Value™ of NT$736.58 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 788 Drug Manufacturers companies, Bora Pharmaceuticals Co ranks better than 84.01% on this metric.

Bora Pharmaceuticals Co's earnings per share without non-recurring items for the three months ended in Dec. 2025 was NT$3.01. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was NT$33.25.

During the past 12 months, Bora Pharmaceuticals Co's average earnings per share (NRI) Growth Rate was 58.70% per year. During the past 3 years, the average earnings per share (NRI) Growth Rate was 41.80% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 72.60% per year. During the past 10 years, the average earnings per share (NRI) Growth Rate was 71.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Bora Pharmaceuticals Co's EPS without NRI or its related term are showing as below:

TPE:6472' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -8.2   Med: 61.15   Max: 141.3
Current: 41.8

During the past 13 years, Bora Pharmaceuticals Co's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 141.30% per year. The lowest was -8.20% per year. And the median was 61.15% per year.

TPE:6472's 3-Year EPS without NRI Growth Rate is ranked better than
84.01% of 788 companies
in the Drug Manufacturers industry
Industry Median: 9.65 vs TPE:6472: 41.80

Bora Pharmaceuticals Co's EPS (Diluted) for the three months ended in Dec. 2025 was NT$2.56. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$23.03.

Bora Pharmaceuticals Co's EPS (Basic) for the three months ended in Dec. 2025 was NT$2.56. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$23.90.


Bora Pharmaceuticals Co  (TPE:6472) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Bora Pharmaceuticals Co EPS without NRI Related Terms


Bora Pharmaceuticals Co EPS without NRI Historical Data

* Premium members only.

The historical data trend for Bora Pharmaceuticals Co's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bora Pharmaceuticals Co EPS without NRI Chart

Bora Pharmaceuticals Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.42 11.78 24.50 21.15 33.57

Bora Pharmaceuticals Co Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.42 20.50 3.39 6.35 3.01

TPE:6472 vs ZTS, UTHR: EPS without NRI Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Bora Pharmaceuticals Co's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bora Pharmaceuticals Co PE Ratio without NRI vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bora Pharmaceuticals Co's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Bora Pharmaceuticals Co's PE Ratio without NRI falls into.


TPE:6472
83GF Score
Bora Pharmaceuticals Co Ltd TPE:6472
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bora Pharmaceuticals Co EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$33.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of NT$33.25 mean?
Bora Pharmaceuticals Co (TPE:6472) has a EPS without NRI of NT$33.25 as of Dec. 2025. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Bora Pharmaceuticals Co and its competitors. According to the industry distribution chart, Bora Pharmaceuticals Co ranks #126 out of 788 companies in the Drug Manufacturers industry, placing it in the top 16%.
Is Bora Pharmaceuticals Co's EPS without NRI too high?
Bora Pharmaceuticals Co's current EPS without NRI is NT$33.25. Based on the distribution chart, Bora Pharmaceuticals Co ranks #126 out of 788 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Bora Pharmaceuticals Co has a GF Score™ of 83/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bora Pharmaceuticals Co's EPS without NRI compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Bora Pharmaceuticals Co ranks #126 out of 788 companies for EPS without NRI. This places Bora Pharmaceuticals Co in the top 16% of its industry — outperforming the majority of peers. The industry median EPS without NRI is 9.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Drug Manufacturers company?
The median EPS without NRI among Drug Manufacturers companies is 9.65, based on 788 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Bora Pharmaceuticals Co and its competitors. For the Drug Manufacturers industry, the median EPS without NRI is 9.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bora Pharmaceuticals Co's current EPS without NRI is NT$33.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bora Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Bora Pharmaceuticals Co (TPE:6472) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$736.58, compared to a current price of NT$396.00 — trading 46.2% below its estimated fair value. The current EPS without NRI is NT$33.25. Bora Pharmaceuticals Co's overall GF Score™ is 83/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Bora Pharmaceuticals Co (TPE:6472), the current EPS without NRI is NT$33.25 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bora Pharmaceuticals Co (TPE:6472) Overvalued in 2026?

Based on GuruFocus' analysis, Bora Pharmaceuticals Co stock appears to be undervalued. The current stock price of NT$396.00 is trading 46.2% below its estimated GF Value™ of NT$736.58. GuruFocus considers Bora Pharmaceuticals Co to be Significantly Undervalued.

Key valuation signals for TPE:6472:

  • EPS without NRI: NT$33.25
  • GF Value™: NT$736.58 vs. price of NT$396.00 (46.2% below fair value)
  • GF Score™: 83/100 with 5 warning signs

No single metric tells the full story. See the TPE:6472 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bora Pharmaceuticals Co Business Description

Other Exchanges BORAY:USA
Address No. 2, Aly. 36, Lane 26, Ruiguang Road, 6th Floor, Neihu District, Taipei, TWN, 114
Bora Pharmaceuticals Co Ltd is a pharmaceutical company based in Taiwan. It covers the pharmaceutical supply chain from research and development to sales and distribution. The main activities of the Company focus on manufacturing and selling generic, brand, and over-the-counter (OTC) drugs, contract development and manufacturing (CDMO), and developing and selling consumer healthcare products. The Group operates in three reportable segments; Sales segment: sale of pharmaceuticals, generics, and healthcare products. CDMO segment: contract development and manufacturing organization of pharmaceuticals. Other segment: Others. Geographically, the company operates in the USA which derives key revenue, Europe, Taiwan, and other regions.
83GF Score

Get the complete analysis for TPE:6472

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$396.00
Price
NT$736.58
GF Value